Rough AI truth score
92/100
Its core biology and treatment history are strong. The biography metaphor captures continuity while current oncology reinforces the book's deeper point: cancer is many evolving diseases, not one enemy awaiting one cure.
Based on three central claims · medium-high confidence
Cancer begins in many tissues and contains heterogeneous genetic and cellular states, but uncontrolled growth and invasion connect the category. Mutations, chromosomal alterations, epigenetic change, immune evasion, and the tumor environment all contribute, matching the book's plural account.
The historical record documents distinct treatment modalities, repeated failures, combination regimens, and later drugs selected by tumor features. Older approaches remain essential, while targeted treatment and immunotherapy extend rather than erase the prior therapeutic history.
Biological diversity within and across cancers makes one intervention implausible, while outcomes have improved dramatically for some cancers and little for others. The categorical prediction cannot be proved, and platform therapies can cross tissue types, but the portfolio view fits current practice.
What this number means. It is an AI-generated first-pass judgment of three central factual or causal claims—not a rating, exhaustive fact-check, or human peer review. Claim credits are 100% for supported, 75% for mostly supported, 50% for mixed, and 25% for weak, then averaged and rounded. Lower confidence means the score should move more as better evidence arrives.
Method three-central-claims/0.1.0 · checked 2026-09-01 · 3/3 selected claims assessed · method and source audit